Ketamine and esketamine clinics represent one of the more important developments in modern psychiatric care: rapid-acting antidepressants for patients who have failed multiple standard agents. The mechanism is NMDA-mediated — distinct from monoamine-based antidepressants — and the clinical experience is fundamentally different. Effect within hours rather than weeks. Two pathways for access, with overlapping clinical outcomes and substantially different access frameworks.
- Class
- NMDA antagonist rapid-acting antidepressants (procedural delivery)
- Mechanism
- NMDA antagonism → glutamate surge → AMPA activation → BDNF release → rapid synaptogenesis. Mechanism differs from monoamine-based antidepressants.
- Typical dose
- Esketamine 56-84 mg intranasal. IV ketamine 0.5 mg/kg over 40 min (off-label protocols vary).
- FDA indications
- Esketamine: treatment-resistant depression, MDD with acute suicidal ideation. IV ketamine: off-label for similar indications.
- Key adverse effects
- Dissociation, sedation, transient BP elevation, nausea, headache, dizziness. Abuse potential. With IV: more pronounced dissociation.
- Representative agents
- Esketamine (Spravato — FDA-approved intranasal), racemic IV ketamine (off-label, widely used in clinics)
Two main clinical pathways: (1) Esketamine (Spravato) — FDA approved, REMS-required clinic, insurance coverage available. (2) IV ketamine clinics — off-label, often cash-pay, less regulation. Clinical outcomes overlap; access pathways differ substantially. Maintenance protocols evolving.
Esketamine — Spravato — is the FDA-approved route. Intranasal administration, REMS-certified clinic, 2-hour monitoring post-dose, no driving same day. Covered by insurance for treatment-resistant depression and for major depression with acute suicidal ideation. Strict regulatory framework. Predictable protocol: twice weekly induction for 4 weeks, then weekly for 4 weeks, then weekly or every 2 weeks for maintenance.
Ketamine and esketamine clinics deliver a glutamatergic antidepressant through a structured service model built around the drug's monitored-administration requirement.
Mechanism note: Ketamine/esketamine clinics deliver rapid, mechanism-distinct antidepressant effect — the structured, monitored service model exists because the drug's acute effects and maintenance needs require it.
IV ketamine — off-label but widely used in ketamine clinics. Lower regulatory burden than Spravato (ketamine itself is FDA-approved for anesthesia; the off-label psychiatric use isn't covered by REMS requirements). Most clinics use 0.5 mg/kg over 40 minutes for depression, similar dosing for the suicidality indication. Cost is typically out-of-pocket and high. Less standardized protocols across clinics.
- Cost
- Esketamine (Spravato): $590-885/dose. IV ketamine clinics typically $400-800/infusion, often cash-pay.
- Generic status
- Esketamine brand-only. Ketamine itself generic but off-label psychiatric use.
- Formulary typical
- Spravato: increasingly covered for TRD with PA. IV ketamine typically not covered, cash-pay.
- Access friction
- Spravato REMS-certified clinic only. IV ketamine clinics vary in quality and protocols. Geographic access concentrated in urban areas.
Prescriber tip: For Spravato, Spravato Connect (Janssen) navigates insurance and REMS. IV ketamine cash-pay typical; verify clinic quality before referring.
Clinical outcomes are similar across the two pathways — both produce rapid antidepressant response in a substantial minority of treatment-resistant patients. The choice often comes down to insurance coverage, geographic access, and patient preference about the experience (intranasal vs IV, REMS-structured vs more flexible).
The acute experience: dissociation lasting roughly 60-90 minutes. Some patients describe it as therapeutically interesting; others as uncomfortable. BP elevation transient. Sedation. The dose-administration period is monitored; afterward, return to baseline within hours.
Ongoing questions: optimal maintenance frequency, long-term safety, abuse/diversion concerns, integration with psychotherapy, durability of effect. The field is still learning what role ketamine will ultimately play in the treatment ladder. For patients with treatment-resistant depression who have insurance support and clinic access, ketamine clinics represent a genuine new option.